Health Trials

Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care

ConditionSmall Bowel Adenocarcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCopenhagen University Hospital at Herlev

About this trial

Small bowel adenocarcinoma is a rare malignancy, and there is limited knowledge about its optimal clinical management and molecular background. The SBAMOL study is an observational biomarker study that aims to identify prognostic and predictive biomarkers. This effort is intended to lay the groundwork for personalized medicine tailored to this specific patient group.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

3
Department of Oncology, Aarhus University Hospital8200, Aarhus N Denmark
Department Surgical Gastroenterology, Copenhagen University Hospital - Rigshospitalet2100, Copenhagen Ø Denmark
Department of Oncology Copenhagen University Hospital - Herlev and Gentofte2730, Herlev Denmark

Sponsors and collaborators

Copenhagen University Hospital at Herlev

Lead sponsor

Aarhus University Hospital

Collaborator

Rigshospitalet, Denmark

Collaborator

University of Copenhagen

Collaborator

Source ClinicalTrials.gov